» Articles » PMID: 34853975

Deoxysphingolipids Upregulate MMP-1, Downregulate TIMP-1, and Induce Cytotoxicity in Human Schwann Cells

Overview
Specialty Biochemistry
Date 2021 Dec 2
PMID 34853975
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Sphingolipids are a heterogeneous class of lipids and essential components of the plasma membrane and plasma lipoproteins. Studies have shown that plasma deoxysphingolipid (DSL), a newly identified sphingolipid class, is increased in diabetic patients and associated with diabetic neuropathy. However, it remains unknown if there is a causal relationship between plasma DSL increase and diabetic neuropathy. Since matrix metalloproteinases (MMPs) play an important role in diabetic neuropathy by degrading extracellular matrix in the peripheral nervous system, we investigated the effect of DSLs on the expression of MMPs and tissue inhibitor of metalloproteinase (TIMPs), and cytotoxicity in human Schwann cells. We quantified protein secretion, gene expression, and collagenase activity, and performed cytotoxicity assays. Results showed that DSLs upregulated MMP-1, downregulated TIMP-1, and induced cytotoxicity in Schwann cells. Furthermore, we quantified DSLs in VLDL, LDL, HDL2, and HDL3 isolated from type 2 diabetes mellitus (T2DM) patients with or without neuropathy. Interestingly, lipidomic analysis showed that only HDL2 isolated from T2DM patients with neuropathy contains significantly higher level of DSLs than that isolated from T2DM patients without neuropathy. Additionally, results showed that HDL2 isolated from T2DM patients with neuropathy was more potent than that isolated from T2DM patients without neuropathy in upregulating MMP-1, downregulating TIMP-1, and stimulating collagenase activity in Schwann cell. Taken together, this study demonstrated for the first time a potential causal relationship between DSLs and diabetic neuropathy and that DSL-containing HDL2 from T2DM patients with neuropathy was more potent than that from T2DM patients without neuropathy in stimulating collagenase activity.

Citing Articles

Causal association between matrix metalloproteinases and diabetic neuropathy: a two-sample Mendelian randomization study.

Bai C, Yang W, Qi G, Yang L, Wu Q, Peng J Front Endocrinol (Lausanne). 2025; 15:1429121.

PMID: 39877847 PMC: 11772099. DOI: 10.3389/fendo.2024.1429121.


How inflammation dictates diabetic peripheral neuropathy: An enlightening review.

Cheng Y, Chen Y, Li K, Liu S, Pang C, Gao L CNS Neurosci Ther. 2023; 30(4):e14477.

PMID: 37795833 PMC: 11017439. DOI: 10.1111/cns.14477.


Circulating Sphingolipids in Insulin Resistance, Diabetes and Associated Complications.

Hammad S, Lopes-Virella M Int J Mol Sci. 2023; 24(18).

PMID: 37762318 PMC: 10531201. DOI: 10.3390/ijms241814015.


Specific Deoxyceramide Species Correlate with Expression of Macular Telangiectasia Type 2 (MacTel2) in a SPTLC2 Carrier HSAN1 Family.

Wilson L, Saba S, Li J, Prasov L, Miller J Genes (Basel). 2023; 14(4).

PMID: 37107689 PMC: 10137565. DOI: 10.3390/genes14040931.

References
1.
Argraves K, Sethi A, Gazzolo P, Wilkerson B, Remaley A, Tybjaerg-Hansen A . S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis. 2011; 10:70. PMC: 3116499. DOI: 10.1186/1476-511X-10-70. View

2.
Bauer J, Huy C, Brenmoehl J, Obermeier F, Bock J . Matrix metalloproteinase-1 expression induced by IL-1beta requires acid sphingomyelinase. FEBS Lett. 2009; 583(5):915-20. DOI: 10.1016/j.febslet.2009.02.008. View

3.
Bauer J, Liebisch G, Hofmann C, Huy C, Schmitz G, Obermeier F . Lipid alterations in experimental murine colitis: role of ceramide and imipramine for matrix metalloproteinase-1 expression. PLoS One. 2009; 4(9):e7197. PMC: 2749204. DOI: 10.1371/journal.pone.0007197. View

4.
Bertea M, Rutti M, Othman A, Marti-Jaun J, Hersberger M, von Eckardstein A . Deoxysphingoid bases as plasma markers in diabetes mellitus. Lipids Health Dis. 2010; 9:84. PMC: 2931514. DOI: 10.1186/1476-511X-9-84. View

5.
Boulton A, Vinik A, Arezzo J, Bril V, Feldman E, Freeman R . Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005; 28(4):956-62. DOI: 10.2337/diacare.28.4.956. View